Journal of Experimental Medicinehttp://jem.rupress.org/icons/banner/title.gifhttp://jem.rupress.org
http://jem.rupress.org/cgi/content/short/213/13/2835?rss=1
Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti–PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.
]]>2016-12-12T08:28:31-08:00info:doi/10.1084/jem.20161462hwp:master-id:jem;jem.20161462The Rockefeller University Press2016-12-12Perspective2131328352840
hw_mjid:jem;213/13/2835